CYAD News and Press, Celyad SA From 03/02/22

MONT-SAINT-GUIBERT, Belgium, March 02, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, t...

Celyad Oncology (NASDAQ:CYAD) voluntarily paused its CYAD-101-002 (KEYNOTE-B79) phase 1b trial (NCT04991948) in colorectal cancer, after it received reports of two fatalities that presented with similar pulmonary findings. The trial is part of a collaboration with Merck & Co. (N...

MONT-SAINT-GUIBERT, Belgium, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, to...

MONT-SAINT-GUIBERT, Belgium, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company...

KEYNOTE-B79 and IMMUNICY-1 clinical trials evaluating the Company’s allogeneic CAR T candidates, CYAD-101 and CYAD-211 respectively, expected to generate key data throughout 2022 Company’s proprietary non-gene edited shRNA technology clinically validated as a novel...

MONT-SAINT-GUIBERT, Belgium, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company...

MONT-SAINT-GUIBERT, Belgium, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that it has rece...

Celyad Oncology (NASDAQ:CYAD) announces the first patient was dosed in the KEYNOTE-B79 Phase 1b trial. The trial will evaluate the Company’s lead developmental candidate, CYAD-101, with Merck's anti-PD-1 therapy, Keytruda (pembrolizumab), in patients with refractory metastatic colorect...

KEYNOTE-B79 Phase 1b trial will evaluate CYAD-101 and KEYTRUDA® (pembrolizumab) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) ASCO-GI conference abstract accepted that highlights KEYNOTE-B79 clinical trial design MONT-SAINT-GUIBE...

The following slide deck was published by Celyad Oncology SA in conjunction with this event. For further details see: Celyad Oncology (CYAD) Presents 2021 American Society of Hematology Meeting Update - Slideshow